FIT colorectal cancer screening reaches many patients, but the follow-up gap remains wide
At-home colorectal cancer screening can bring prevention out of the clinic and into the home, where a mailed stool test may feel less disruptive than arranging an in-person procedure. In this large retrospective study from a multi-state health system, that convenience translated into meaningful participation: 59% of patients who received a fecal immunochemical test, or FIT, returned it. Among those eligible for repeat testing, 73% completed a second test.
Those numbers matter because FIT works only when the process does not stop at the mailbox. A positive result is not a diagnosis; it is a trigger for colonoscopy, the test that can locate advanced lesions, remove precancerous polyps, and confirm or exclude cancer. Here, 59% of patients with abnormal FIT results had a colonoscopy within 12 months. The remaining group represents a clinically important gap, because the benefit of earlier detection disappears if abnormal screening results fail to connect patients to definitive care.
A large real-world cohort across the screening continuum
The analysis included 158,128 age-eligible adult patients mailed a FIT between January 2019 and March 2025. Investigators evaluated three linked steps in the screening pathway: initial participation, continued participation, and connection to follow-up care after an abnormal result. Initial and continued participation were defined by FIT return, while follow-up care was defined as colonoscopy within 12 months after an abnormal FIT.
This design captures something routine cancer screening studies often miss: the pathway is not a single event. It is a sequence of behaviors, each vulnerable to dropout. A patient may return the first kit and still miss the second. Another may complete repeated screening yet never proceed to colonoscopy after an abnormal result. In practical terms, the system has to function at both ends—getting the test done and making sure the abnormal result leads somewhere.
Race and ethnicity, language, payor, and geography all shaped screening behavior at each step. The pattern suggests that access barriers do not end when a home kit arrives. They can persist through reminder systems, result communication, test comprehension, scheduling logistics, transportation, and the ability to navigate a specialty referral after a positive screen. Screening that appears “low-barrier” on paper can still become difficult once a patient needs a colonoscopy, especially when the health system and the patient live on different sides of the same process.
Why home testing succeeds, and where it breaks down
FIT has a clear biological advantage for population screening: it detects occult blood from neoplastic lesions, offering a noninvasive way to identify patients who need diagnostic follow-up. That simplicity helps explain why mailed kits can improve uptake in groups that might not otherwise complete screening. The test is inexpensive, familiar, and far easier to complete than colonoscopy, which requires bowel preparation, time off work, escort arrangements, and procedural tolerance.
Yet the same simplicity can create an illusion of completeness. A home test is only the first half of a safety net. When the result is abnormal, the downstream steps become more resource-intensive and more vulnerable to inequity. A patient who can quickly mail back a stool sample may still struggle to secure a colonoscopy within a year, and delays in diagnostic evaluation can erode the value of earlier screening. In colorectal cancer prevention, the system must not only identify risk; it must respond to it.
The observed differences by race and ethnicity, language, payor, and geography point to structural factors rather than isolated patient choices. Language discordance can interfere with risk communication and instructions. Payor status may shape referral speed and access to procedure scheduling. Geography can determine whether a colonoscopy is available nearby or requires travel that many patients cannot easily manage. The study does not measure those mechanisms directly, but the pattern is consistent with them.
What the data say about persistence in screening
The strongest signal in the cohort may be the 73% return for a second FIT among those eligible for repeat testing. Persistence matters because annual screening is built on repetition; one completed test does not maintain protection indefinitely. In a program that depends on yearly engagement, repeat participation becomes a marker of trust in the system, effective reminders, and workable access.
Still, a 27% dropout rate at the repeat-test stage is substantial in a prevention program meant to reach large populations. The missed second test may reflect forgotten reminders, competing life demands, confusion about the schedule, or disengagement after an initially normal result. Whatever the cause, the result is the same: the screening pathway weakens over time unless the health system keeps pulling patients back in.
The follow-up stage is more concerning. Colonoscopy within 12 months after an abnormal FIT was not universal, even though that step is central to resolving a positive screen. For a screening strategy built to lower colorectal cancer mortality, incomplete diagnostic completion limits the benefit. Positive stool tests that do not lead to colonoscopy remain unresolved clinical alarms.
Screening programs need more than mailed kits
This study reinforces a straightforward point for public health teams and health systems: access to FIT is necessary, but it is not sufficient. Mail-based screening may broaden reach, but the care model has to include navigation, reminder systems, and reliable colonoscopy access after abnormal results. Without that infrastructure, the system detects risk faster than it can close the loop.
Because the cohort spans multiple years and a large multi-state delivery system, the findings reflect real-world operations rather than an idealized trial setting. That makes the results especially relevant for health systems trying to improve colorectal cancer screening at scale. The data also suggest that interventions should not be limited to first-time participation. Repeat screening and diagnostic follow-up need equal attention if the program is going to reduce disparities rather than reproduce them.
The study’s observational design cannot prove why some patients completed every step while others dropped out, and it does not quantify the relative contribution of each barrier. Even so, the pattern is hard to ignore: home testing can expand entry into screening, but the pathway still fractures along social and geographic lines. In colorectal cancer prevention, the critical failure point may be less about whether patients ever received a FIT than whether the system was ready when that FIT came back abnormal.